Morphine Infusion (Preservative-Free) is a compounded sterile solution of morphine sulfate prepared without benzyl alcohol or other preservatives, for continuous subcutaneous infusion (CSCI) or intravenous infusion. Bayview Pharmacy compounds it at 5 mg/mL and 20 mg/mL, and at other concentrations when a prescriber orders them, filled into infusion bags. It is part of our hospice and palliative care compounding line.
This page is written for prescribers and for the hospice nurses and family caregivers who manage an infusion at home. It describes the preparation and summarizes what the palliative care literature reports. It is not medical advice, and nothing on this page recommends a drug or a dose for any patient. The prescribing clinician decides whether an opioid infusion is appropriate, which opioid to use, and at what rate.
What is it used for?
In hospice and palliative care, morphine is prescribed for two symptoms. One is pain. The other is dyspnea, the sensation of breathlessness, sometimes described as air hunger. A continuous parenteral infusion is generally considered when the oral route has failed or is unavailable, for example because of dysphagia, obtundation, persistent vomiting, or bowel obstruction. The decision to begin an opioid infusion, and the choice among morphine, hydromorphone, fentanyl, and sufentanil, belongs to the prescribing clinician. Bayview also compounds preservative-free hydromorphone infusion and the wider set of hospice and palliative care preparations, including magic mouthwash for oral discomfort.
How does it work?
Morphine is an agonist at the mu-opioid receptor. In plain terms, it turns down the brain's alarm signal for pain, and it reduces the sensation of breathlessness. That is why one drug is used for two symptoms that can seem unrelated. It does not treat the underlying disease.
Why is a concentrated, preservative-free preparation compounded?
There are three documented reasons, and the first is the main one.
Subcutaneous tissue absorbs roughly up to 3 mL per hour. That volume ceiling is the entire rationale for the 20 mg/mL strength. Above roughly 3 mL/hr the tissue cannot take up the fluid, so a high hourly dose simply cannot be delivered subcutaneously at commercially available dilute concentrations. The 5 mg/mL strength covers typical infusion requirements. The 20 mg/mL strength exists for opioid-tolerant patients, and to keep a 50, 100, or 150 mL bag running long enough that a nurse is not driving to the home every day to change it. Bag size is chosen as rate multiplied by the desired change interval.
Preservative-free matters at a continuous infusion site. Benzyl alcohol and other preservatives cause local tissue irritation at continuous subcutaneous sites and accumulate when infusion volumes are high, so preservative-free preparations are used for this route.
Supply. Morphine injection has appeared on FDA and ASHP drug shortage lists, and persistent shortages of commercial morphine injection are an additional documented driver of compounding.
Concentrations and bag sizes
The table below lists what Bayview routinely compounds. Bag size is a practical choice, infusion rate multiplied by the interval between nurse visits, not a clinical recommendation. The prescriber specifies the concentration, the volume, and the container.
| Concentration | Volumes filled | Notes |
|---|---|---|
| Morphine sulfate 5 mg/mL, preservative-free | 100 mL or 150 mL bag | Covers typical continuous infusion requirements |
| Morphine sulfate 20 mg/mL, preservative-free | 50 mL, 100 mL, or 150 mL bag | Used when the ordered hourly dose would exceed the subcutaneous volume ceiling at a dilute concentration, or to extend the time between bag changes |
| Other concentrations | As ordered | Compounded to the prescriber's written order |
| Containers | Infusion bags | Specify the pump on the prescription |
Concentrations and volumes are listed for reference only and are not a statement that any strength or volume is appropriate for a particular patient. Dispensing more than one bag is a supply arrangement and is not a dosing instruction.
How is it given?
Continuous subcutaneous infusion is the workhorse route in the home when the oral route fails and intravenous access is absent or burdensome. Morphine, hydromorphone, fentanyl, and sufentanil are all suitable for subcutaneous administration. A 25- or 27-gauge butterfly needle is placed in the upper arm, shoulder, abdomen, or thigh, avoiding the chest wall, and connected to an ambulatory infusion pump. The same preparation can be run intravenously when a line is already in place. Evidence for intravenous-to-subcutaneous conversion is weak; many practitioners use a 1:1 ratio.
Caring for the infusion site
A subcutaneous site may remain in place for up to about a week unless a local reaction develops. Rotate the site if you see redness, hardness or firm swelling under the skin (induration), or fluid leaking around the needle. Avoid placing a site in tissue that is swollen with fluid (edematous) or that has been irradiated. Tell the hospice nurse about any site problem, and about a pump alarm you do not understand. Do not reprogram or restart the pump on your own. Call the hospice.
Dosing and titration as reported in the literature
Dosing is the prescriber's decision. The following describes the approach reported in the palliative care literature and is provided for reference only. It is not a dosing recommendation.
- Convert the patient's current 24-hour opioid requirement to an intravenous or subcutaneous equivalent, then divide by 24 to obtain the basal hourly rate.
- A loading bolus is described, because steady state on a continuous infusion takes hours to reach.
- Demand (patient-controlled) boluses are commonly described at 50 to 150% of the hourly rate, with a lockout of about 20 minutes.
- Reassessment every 30 to 60 minutes until symptoms are controlled is described.
Kidney function and morphine's metabolites
This is the point most specific to morphine. Morphine is metabolized to glucuronide metabolites, morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G), which accumulate when kidney function declines and may cause opioid neurotoxicity. That is why prescribers often move away from morphine as renal function worsens.
To be accurate about the alternatives: hydromorphone follows a similar pattern through its own glucuronide metabolite, so describing hydromorphone as simply "safe in renal failure" overstates the case. Fentanyl and methadone have no clinically significant active metabolites. The literature recommends dose reduction of approximately 25% at a creatinine clearance of 10 to 50 mL/min and approximately 50% at a creatinine clearance below 10 mL/min.
Side effects and safety
Respiratory depression is the principal risk of opioid therapy. As reported in the palliative care literature, opioids correctly titrated to symptom relief do not cause respiratory depression; the risk lies in non-proportional dose escalation, in opioid-naive patients, and in co-administration of an opioid with a benzodiazepine.
Equianalgesic conversion is the most common source of serious opioid error. Published conversion ratios are approximations, and incomplete cross-tolerance warrants a reduction of 25 to 50% when rotating from one opioid to another.
Other effects reported with morphine include sedation, constipation, nausea, pruritus (itching, which with morphine is related to histamine release), urinary retention, and myoclonus. Constipation is universal with continuous opioid therapy, and a bowel regimen is planned alongside it rather than after the fact.
Who should not receive it?
This decision belongs to the prescribing clinician, and in hospice the balance of risk and benefit is different from other settings. The considerations below are drawn from the standard morphine sulfate labeling and are listed for reference, not as a recommendation.
Morphine is contraindicated in anyone with a known hypersensitivity to morphine, in significant respiratory depression, in acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment, and in known or suspected gastrointestinal obstruction including paralytic ileus (MedlinePlus). Concurrent benzodiazepines or other central nervous system depressants raise the risk of profound sedation and respiratory depression, which is one of the settings where respiratory depression concentrates. As covered above, declining kidney function is a reason prescribers often move away from morphine rather than a strict contraindication.
Tell the hospice team about all medications the patient takes, including anything started by another prescriber, and about any known drug allergy.
Storage, security, and disposal
Store exactly as directed on the label. Morphine is a Schedule II controlled substance and is a target for diversion. Keep it in a secure place, a lock box or a locked cabinet, and out of the sight and reach of children, visitors, and anyone else in the home. Keep track of what has been dispensed and what remains. Never give it to anyone other than the patient it was dispensed for; sharing a controlled substance is a federal offense and can be fatal to someone who is not opioid-tolerant.
Do not put unused bags in the household trash. Under the CMS hospice condition of participation at 42 CFR 418.106, the hospice must have written policies for the management and disposal of controlled drugs in the patient's home, and must counsel the patient and family on those policies, and document that counseling, when controlled drugs are first ordered. Follow your hospice's written disposal procedure, and ask the hospice nurse if anything about it is unclear.
Sterile compounding and beyond-use dates
Bayview prepares this as a sterile compounded preparation under USP General Chapter <797>. You can read how we handle sterile compounding. The 2023 revision of <797>, official November 1, 2023, replaced the former low-, medium-, and high-risk levels with Category 1, Category 2, and Category 3 compounded sterile preparations. Category 1 preparations are compounded in a primary engineering control located in an unclassified segregated compounding area and carry short beyond-use dates. Category 2 preparations require a cleanroom suite, with beyond-use dates assigned per the chapter's Table 13. Category 3 permits longer beyond-use dates per Table 14, but requires sterility testing and extended environmental monitoring.
One practical point matters for scheduling deliveries and bag changes: the assigned beyond-use date, not the chemical stability of the molecule, usually governs how long a preparation may be used. The beyond-use date for each dispense is assigned according to the applicable USP <797> category and the testing performed, and is printed on the label. Use the date on the label.
Clinical details for prescribers
Regulatory status. Morphine sulfate is a Schedule II controlled substance. 21 CFR 1306.11 requires a written, signed prescription for a Schedule II controlled substance. A facsimile prescription serves as the original written prescription, with no follow-up hard copy required, in three situations that commonly apply to this preparation: (a) a Schedule II narcotic compounded for direct parenteral administration by intravenous, intramuscular, subcutaneous, or intraspinal infusion; (b) a resident of a long-term care facility; and (c) a patient enrolled in a hospice program. Electronic prescribing for controlled substances is also accepted.
Compounding status. Compounded under section 503A of the Federal Food, Drug, and Cosmetic Act. Compounded preparations are not FDA-approved, and FDA does not verify their safety, effectiveness, or quality before marketing. Each preparation is compounded for an identified individual patient on a valid prescription; anticipatory compounding is permitted only in limited quantities based on a documented history of receiving valid prescriptions. Bayview does not supply office-use stock, agency stock, or fillable hospice kits.
Formulation. Morphine sulfate, preservative-free, 5 mg/mL and 20 mg/mL; other concentrations compounded to order. Filled into infusion bags at 50 mL, 100 mL, and 150 mL. Prepared as a sterile compounded preparation under USP <797>; the beyond-use date is assigned by category and testing performed, and is printed on the label.
Clinical points as reported in the literature:
- Subcutaneous absorption is limited to roughly 3 mL/hr, which constrains the achievable hourly dose at dilute concentrations and is the rationale for the 20 mg/mL preparation
- CSCI is used when the oral route fails (dysphagia, obtundation, vomiting, bowel obstruction) and IV access is absent or burdensome; 25- or 27-gauge butterfly in upper arm, shoulder, abdomen, or thigh, avoiding the chest wall; a site may remain up to about a week absent local reaction; rotate on redness, induration, or leakage; avoid edematous or irradiated tissue
- Morphine, hydromorphone, fentanyl, and sufentanil are all suitable subcutaneously; IV:SQ conversion evidence is weak and many practitioners use 1:1
- Titration as reported: convert the 24-hour opioid requirement to an IV/SQ equivalent, divide by 24 for the basal rate, give a loading bolus because steady state takes hours, set demand boluses at 50 to 150% of the hourly rate with a lockout of about 20 minutes, and reassess every 30 to 60 minutes until controlled
- M3G and M6G accumulate in renal impairment with a risk of neurotoxicity (myoclonus, hyperalgesia, agitated delirium); approximately 25% dose reduction at CrCl 10 to 50 mL/min and approximately 50% at CrCl <10 mL/min is recommended. Hydromorphone accumulates via its own glucuronide and is not simply "safe in renal failure"; fentanyl and methadone have no clinically significant active metabolites
- Incomplete cross-tolerance warrants a 25 to 50% reduction when rotating opioids; published equianalgesic ratios are approximations, and conversion is the most common source of serious error
- Respiratory depression risk concentrates in non-proportional dose escalation, opioid-naive patients, and benzodiazepine co-administration; opioids correctly titrated to symptom relief are not reported to cause respiratory depression
- 42 CFR 418.106 requires hospice written policies on management and disposal of controlled drugs in the home, with counseling and documentation at the time controlled drugs are first ordered
Ordering: send a written, signed prescription, an EPCS electronic prescription, or a facsimile as permitted above to Bayview Pharmacy, 3844 Post Rd, Warwick, RI 02886, fax 401-284-4506. Specify concentration, total volume, container and pump type, rate, and any demand bolus and lockout. Dosing decisions remain the prescriber's responsibility. Account setup, licensing, and ordering are covered on our for providers page.
This is a prescription compounded preparation and is not FDA-approved. Morphine is a Schedule II controlled substance. This information is educational, is not medical advice, and is not a recommendation to use any drug or any dose for any patient. The prescribing clinician determines whether an opioid infusion is appropriate and sets the drug, concentration, and rate.
References
- MedlinePlus: Morphine
- 21 CFR 1306.11: Requirement of prescription (Schedule II)
- 42 CFR 418.106: Hospice condition of participation, drugs and biologicals
- USP General Chapter <797> Pharmaceutical Compounding, Sterile Preparations
- FDA Drug Shortages database
- Section 503A, Federal Food, Drug, and Cosmetic Act
